Clinic
Burke Pediatrics, LLC
Burke Pediatrics, LLC was paid $1.79M by Medicaid between Jan 2018 and Jul 2023, across 58 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 34% of everything it billed.
33Billing provider infoBURKE PEDIATRICS, LLC
BURKE, VA 22015
BURKE, VA 22015
33aNPI1043585029assigned 03/09/2012
33bProvider typePrimary Care Clinic/Center
28Total paid$1.79M
24GClaims52,605
24DCodes billed58
24AFirst – last monthJan 2018 – Jul 2023
Compared with peers
Next to other Primary Care Clinic/Center providers in Virginia
Rank by total paid#10 of 80
Median peer was paid$108K
This provider vs. median17×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,680 | $421K | |
| 2019 | 13,449 | $393K | |
| 2020 | 8,565 | $293K | |
| 2021 | 8,687 | $266K | |
| 2022 | 6,603 | $293K | |
| 2023 | 2,621 | $125K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 34% | 7,680 | 6,666 | $610K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 16% | 5,176 | 4,702 | $288K |
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | 7.4% | 5,519 | 4,891 | $133K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 6.3% | 978 | 880 | $113K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 6.0% | 1,474 | 1,408 | $108K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 5.8% | 1,293 | 1,242 | $105K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.1% | 1,198 | 1,157 | $91K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.5% | 650 | 573 | $44K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.1% | 3,012 | 1,424 | $38K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.6% | 2,200 | 2,046 | $29K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.6% | 264 | 234 | $29K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 633 | 607 | $29K |
46 more codes
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.3% | 2,335 | $22K |
| 90686 | 1.1% | 1,747 | $20K | |
| 90651 | <1% | 366 | $17K | |
| 87081 | <1% | 1,696 | $12K | |
| 92551 | <1% | 1,205 | $11K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 726 | $10K |
| 99177 | <1% | 2,749 | $10K | |
| 96127 | <1% | 2,088 | $9K | |
| 90670 | <1% | 481 | $9K | |
| 90734 | <1% | 261 | $8K | |
| 96160 | <1% | 3,205 | $6K | |
| 99051 | <1% | 1,132 | $4K | |
| 90698 | <1% | 249 | $4K | |
| 99401 | <1% | 269 | $3K | |
| 90620 | <1% | 73 | $3K | |
| 90633 | <1% | 201 | $3K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 919 | $2K |
| 0001A | <1% | 61 | $2K | |
| 90680 | <1% | 162 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 58 | $2K |
| 86580 | <1% | 257 | $2K | |
| 90707 | <1% | 78 | $1K | |
| 90716 | <1% | 53 | $1K | |
| 99174 | <1% | 188 | $1K | |
| 96161 | <1% | 454 | $1K | |
| 90744 | <1% | 92 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 49 | $887.86 |
| 0071A | <1% | 18 | $720.00 | |
| 90685 | <1% | 67 | $693.00 | |
| 94760 | <1% | 436 | $652.93 | |
| 0072A | <1% | 15 | $600.00 | |
| 81002 | <1% | 197 | $517.51 | |
| 99188 | <1% | 26 | $482.33 | |
| 0002A | <1% | 12 | $480.00 | |
| 90715 | <1% | 25 | $451.93 | |
| A7006 | Administration set, with small volume filtered pneumatic nebulizer | <1% | 49 | $303.08 |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 65 | $225.00 |
| 93000 | <1% | 14 | $161.91 | |
| 96156 | <1% | 77 | $159.11 | |
| 90461 | <1% | 48 | $125.85 | |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 50 | $41.52 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 49 | $7.06 |
| 91300 | <1% | 112 | $0.73 | |
| 97802 | 0% | 56 | $0.00 | |
| 91307 | 0% | 33 | $0.00 | |
| 99072 | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGARNER, FREDRIC (MANGING PARTNER)